secwatch.observer — SEC 8-K summary
======================================

Issuer:     Medicus Pharma Ltd. (MDCX)
CIK:        0001997296
Form:       8-K
Filed at:   2025-06-30T23:59:59+00:00
Accession:  0001062993-25-012231
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Medicus Pharma to acquire Antev Ltd. for ~17% equity stake + up to $65M contingent milestone payments
--------------------------------------------------------------------------------

- Medicus will issue 2,666,600 common shares (~17% of outstanding) to acquire all Antev shares on a fully diluted basis.
- Antev shareholders eligible for up to $65M in contingent consideration tied to FDA Phase 2 and NDA approvals for Teverelix.
- Transaction expected to close before end of August 2025, subject to Antev shareholder approval and other conditions.
- Antev's lead asset Teverelix targets two indications: acute urinary retention (Phase 2b) and high-CV-risk advanced prostate cancer (Phase 2b).
- Consideration shares subject to 9-month staggered lock-up and 36-month voting agreement with Medicus management.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1997296/000106299325012231/0001062993-25-012231-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1997296/000106299325012231/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001062993-25-012231

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer